CareDx’s ALAMO Study: A New Era in Lung Transplant Surveillance

CareDx Inc ((CDNA)) announced an update on their ongoing clinical study.

CareDx Inc. is currently conducting the AlloSure Lung Assessment and Metagenomics Outcomes Study (ALAMO), a prospective, multi-center registry aimed at evaluating the diagnostic performance of LungCare™ (AlloSure®-Lung, AlloMap Lung, and HistoMap) in detecting rejection and allograft infections in lung transplant recipients. This study is significant as it seeks to improve post-transplant surveillance and patient outcomes.

The intervention being tested is LungCare, which includes AlloSure-Lung, AlloMap Lung, and HistoMap. These are designed to monitor lung transplant patients for signs of rejection and infection, thereby aiding in timely and effective medical intervention.

The study is observational in design, utilizing a case-control model with a prospective time perspective. It involves a cohort of lung transplant recipients, with data collected through a web-based electronic data collection system. The primary goal is to observe the real-world application and outcomes of LungCare in patient management.

The study began on October 29, 2021, and is currently recruiting participants. The last update was submitted on June 30, 2025, indicating ongoing progress. These dates are crucial as they reflect the study’s timeline and the commitment to advancing transplant care.

This study update could positively impact CareDx’s stock performance by demonstrating the company’s commitment to innovation in transplant diagnostics. It may also influence investor sentiment favorably, given the potential for improved patient outcomes. Competitors in the transplant diagnostics industry may need to take note of these advancements.

The AlloSure Lung Assessment and Metagenomics Outcomes Study is ongoing, with further details available on the ClinicalTrials portal.